Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for MDGL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2005. Start Trial.
Date Value
June 30, 2026 346.72M
March 31, 2026 345.61M
December 31, 2025 346.61M
September 30, 2025 345.32M
June 30, 2025 122.90M
March 31, 2025 118.76M
December 31, 2024 118.59M
September 30, 2024 118.26M
June 30, 2024 117.51M
March 31, 2024 117.18M
December 31, 2023 116.67M
September 30, 2023 116.05M
June 30, 2023 99.25M
March 31, 2023 83.96M
December 31, 2022 49.29M
September 30, 2022 49.05M
June 30, 2022 48.85M
March 31, 2022 0.283M
December 31, 2021 0.387M
September 30, 2021 0.491M
June 30, 2021 0.594M
March 31, 2021 0.387M
December 31, 2020 0.468M
September 30, 2020 0.548M
June 30, 2020 0.197M
Date Value
March 31, 2020 0.279M
December 31, 2019 0.361M
September 30, 2019 0.441M
June 30, 2019 0.52M
March 31, 2019 0.598M
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 0.00
March 31, 2018 0.00
December 31, 2017 0.00
September 30, 2017 0.00
June 30, 2017 0.00
March 31, 2017 0.00
December 31, 2016 0.00
September 30, 2016 0.00
June 30, 2016 0.032M
March 31, 2016 2.332M
December 31, 2015 0.00
September 30, 2015 6.967M
June 30, 2015 9.282M
March 31, 2015 11.60M
December 31, 2014 13.91M
September 30, 2014 16.22M
June 30, 2014 18.52M
March 31, 2014 20.90M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Exelixis, Inc. 165.93M
Karyopharm Therapeutics, Inc. 255.12M
ACADIA Pharmaceuticals, Inc. 59.55M
Alnylam Pharmaceuticals, Inc. 2.942B
Anika Therapeutics, Inc. 23.32M